Company profile
MILESTONE PHARMACEUTICALS INC.
NASDAQ:MISTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CARDAMYST | approved | $0.6MQ2 2026 | 4 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03464019 | phase3 | terminated | 2018-06-18 | 2023-01-20 | Milestone Pharmaceuticals Inc. | Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). |
| NCT02296190 | phase2 | completed | 2015-03-27 | 2016-12-01 | Milestone Pharmaceuticals Inc. | Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm |
| NCT04952610 | phase3 | completed | 2021-12-13 | 2026-04-10 | Milestone Pharmaceuticals Inc. | Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia |
| NCT04467905 | phase2 | completed | 2020-11-19 | 2023-08-03 | Milestone Pharmaceuticals Inc. | ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2 |
| NCT06716021 | phase3 | recruiting | 2026-08-20 | 2028-12-01 | Milestone Pharmaceuticals Inc. | ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 218571 | 2025-12-12 | NDA | MILESTONE PHARMACEUTICALS USA INC | |||||
Loading… | ||||||||